IL17A and Hepatic fibrosis: Patients with the dominant genotype (GA + AA) of the IL17A-G197A polymorphism exhibited 3.91 times greater odds of experiencing at least a one-stage increase in liver fibrosis compared to those with the GG genotype (adjusted OR = 3.91, 95% CI: 1.33–12.34).